Immune to Cancer: The CRI Blog
-
What Cancer Patients Need to Know About the Opdivo Approval
Now that Opdivo (nivolumab) has been FDA approved for two cancer types, many patients are wondering: what’s…
-
Phase 3 Trial of Nivolumab Shows Survival Advantage in Lung Cancer
The results of a phase III trial are clear: the PD-1 checkpoint inhibitor nivolumab improves survival for…
-
Smoke Screens: Searching for the Causes of Lung Cancer
On the 50th anniversary of the Surgeon General’s report, a look back at the science and politics…